Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/554,181	NALDINI ET AL.	
Examiner	Art Unit	

	CA	THERINE HIBBERT	1636	
The MAILING DATE of this commun	ication appears	on the cover sheet with th	e correspondence add	ress
THE REPLY FILED <u>11 January 2010</u> FAILS TO P	LACE THIS APPL	ICATION IN CONDITION F	OR ALLOWANCE.	
1. The reply was filed after a final rejection, but application, applicant must timely file one of application in condition for allowance; (2) a for Continued Examination (RCE) in complia periods:	prior to or on the state the following replies Notice of Appeal (v	same day as filing a Notice o es: (1) an amendment, affida vith appeal fee) in compliand	of Appeal. To avoid abar avit, or other evidence, w se with 37 CFR 41.31; or	which places the r (3) a Request
a) The period for reply expiresmonths to b) The period for reply expires on: (1) the mailing no event, however, will the statutory period for Examiner Note: If box 1 is checked, check eith MONTHS OF THE FINAL REJECTION. See	ng date of this Adviso or reply expire later the ther box (a) or (b). O	ory Action, or (2) the date set for nan SIX MONTHS from the mai	ling date of the final rejection	on.
Extensions of time may be obtained under 37 CFR 1.136 have been filed is the date for purposes of determining the under 37 CFR 1.17(a) is calculated from: (1) the expiration set forth in (b) above, if checked. Any reply received by may reduce any earned patent term adjustment. See 37 NOTICE OF APPEAL	he period of extension on date of the shorte the Office later than	on and the corresponding amou ened statutory period for reply o	nt of the fee. The appropria riginally set in the final Offic	ate extension fee be action; or (2) as
2. The Notice of Appeal was filed on A filing the Notice of Appeal (37 CFR 41.37(a) Notice of Appeal has been filed, any reply mAMENDMENTS), or any extension	thereof (37 CFR 41.37(e)),	to avoid dismissal of the	
3. The proposed amendment(s) filed after a fin (a) They raise new issues that would requ (b) They raise the issue of new matter (se (c) They are not deemed to place the app appeal; and/or (d) They present additional claims without	uire further conside se NOTE below); plication in better fo	eration and/or search (see N	OTE below); reducing or simplifying t	
NOTE: See Continuation Sheet. (Se 4. The amendments are not in compliance with 5. Applicant's reply has overcome the followin 6. Newly proposed or amended claim(s) non-allowable claim(s).	h 37 CFR 1.121. S g rejection(s):	see attached Notice of Non-C	,	,
7. For purposes of appeal, the proposed amen how the new or amended claims would be re The status of the claim(s) is (or will be) as fo Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1 and 3-18. Claim(s) withdrawn from consideration:	ejected is provided illows:		will be entered and an e	xplanation of
AFFIDAVIT OR OTHER EVIDENCE				
 The affidavit or other evidence filed after a fi because applicant failed to provide a showin was not earlier presented. See 37 CFR 1.12 	ng of good and suff 16(e).	ficient reasons why the affid	avit or other evidence is	necessary and
 The affidavit or other evidence filed after the entered because the affidavit or other evider showing a good and sufficient reasons why it 	nce failed to overc	ome <u>all</u> rejections under app	eal and/or appellant fail	s to provide a
10. The affidavit or other evidence is entered. A REQUEST FOR RECONSIDERATION/OTHER	·		•	
 11. The request for reconsideration has been on the non-entry of the claim amendments sure. 12. Note the attached Information Disclosure States. 13. Other: 	<u>ıbmitted after-final</u>	for reasons provided above	renders applicants argu	
/ Christopher S. F. Low / Supervisory Patent Examiner, Art Unit 1636		Catherine Hibbert Examiner AU1636		

Continuation of 3. NOTE: The proposed amendment filed after a final rejection will not be entered because the proposed claim amendment does not further limit the claims because the addition of the limitation "eukaryotic" is not further limiting because the claims were already limited to "animal" which reads on the limitation "eukaryotic". Please see Attachment for further reasoning..